Maryam   Lustberg, MD, MPH

Maryam Lustberg, MD, MPH

Yale Cancer Center/Smilow Cancer Hospital

Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Breast Cancer; Chief, Breast Medical Oncology

Expertise: Breast CancerBreast CancerBreast Medical OncologyBreast Medical OncologyInternal MedicineInternal Medicine

Maryam Lustberg, MD, MPH, is Director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center, and Chief of Breast Medical Oncology at Yale Cancer Center. She is also an Associate Professor of Medicine (Medical Oncology). She has been recognized for her patient-focused care with awards that include being rated by Forbes as one of the top breast medical oncologists in the nation and named to the Castle Connolly list of “Regional Top Doctors,” and “Exceptional Women in Medicine” for 2020. She is currently participating in the American Society of Clinical Oncology (ASCO) Leadership Development Program.

With an emphasis on improving the long-term outcomes for patients with breast cancer who have developed side effects associated with treatment, Dr. Lustberg will continue her research efforts at Yale. She is also focused on investigating novel blood-based biomarkers to identify recurrence and treatment toxicity earlier. She is an NCI-funded investigator and active in both ALLIANCE and SWOG Cancer Cooperative Groups. Dr. Lustberg collaborates widely with researchers from around the world, thriving in creating innovative multidisciplinary scientific teams. Her mentorship has been recognized by numerous awards including Best Teacher Award by Hematology Oncology Fellows and the Shining Star Award for Medical Student Mentorship.
Nationally, Dr. Lustberg is a member of the ASCO Annual Meeting Education Committee, Patient and Survivor Care Education Committee, and Neuropathy Expert Guideline Panel. She is actively engaged in national patient advocacy organizations with a focus on improving shared decision making and increasing patient engagement in clinical trials. In addition, she serves as the President Elect and on the Board of Directors for the international organization Multinational Association of Supportive Care in Cancer (MASCC). She serves as an Associate Editor for the Journal of Cancer Survivorship. In the last decade, she has published over 140 peer-reviewed publications and book chapters.
Dr. Lustberg received her medical degree from the University of Maryland where she also completed her residency and went on to complete a fellowship in medical oncology and in breast medical oncology at The Ohio State University before joining the faculty in 2010. She earned a Master's in Public Health from The Ohio State University in 2013.
Education & Training
MPH
The Ohio State University, Clinical Investigation (2010)
MD
University of Maryland (2003)
Departments & Organizations
Cancer Prevention and ControlCenter for Breast CancerCOPPER CenterInternal MedicineMedical OncologySubset Medical Oncology FacultyYale Cancer CenterYale Medicine

No Clipping

No Research/Citations

Study: Patient’s Genetic Characteristics May Help Differentiate HER2-Low Advanced Breast Cancers and Guide Treatment Selection

The targeted therapy trastuzumab deruxtecan (T-Dxd), an antibody drug conjugate, is now an approved treatment of HER2-low advanced breast cancers. In a new study led by Yale Cancer Center researchers at Yale School of Medicine, their findings revealed important differences in the genetic makeup of HER2-low advanced breast cancers — a discovery that could lead to better treatment options for patients.
06-Dec-2023 07:05:10 PM EST

Yale Cancer Center Experts Present New Research at Leading Breast Cancer Symposium

Yale Cancer Center researchers at Yale School of Medicine will present new research at the 46th annual San Antonio Breast Cancer Symposium (SABCS) from December 5 to 9. The international symposium provides leading-edge breast cancer information on prevention, etiology, diagnosis, and therapy as well as experimental biology. This year’s symposium, at the Henry B.
29-Nov-2023 10:05:37 AM EST

No Quotes

Available for logged-in users onlyLogin HereorRegister

No Video

close
0.08838